Tags

Type your tag names separated by a space and hit enter

Validation of a novel point-of-care nerve conduction device for the detection of diabetic sensorimotor polyneuropathy.
Diabetes Care. 2006 Sep; 29(9):2023-7.DC

Abstract

OBJECTIVE

The diagnosis of diabetic sensorimotor polyneuropathy using objective electrophysiological tests is hindered by limited access to the specialized laboratories and technicians that perform and interpret them. We evaluated the performance characteristics of a novel portable and automated point-of-care nerve conduction study device, which can be operated by nontechnical personnel, and compared it with conventional nerve conduction studies performed in a specialist setting.

RESEARCH DESIGN AND METHODS

Seventy-two consecutive patients with diabetes (8 type 1, 64 type 2) from a diabetes and a neuropathy outpatient clinic were evaluated concurrently with conventional nerve conduction studies (the reference standard) and the point-of-care device for sural nerve function (sural nerve amplitude potentials in microvolts [microV]).

RESULTS

Sural nerve amplitude potentials measured by the point-of-care device shared very strong correlation with the reference standard (Spearman's correlation coefficient 0.95, P < 0.001). The Bland and Altman method yielded agreement despite a small systematic underestimation by the point-of-care device of 1.2 +/- 3.4 microV. Despite this small systematic bias, the sensitivity and specificity of normal and abnormal sural nerve amplitude potentials measured by the point-of-care device for the detection of diabetic sensorimotor polyneuropathy defined by standard clinical and electrophysiological criteria were 92 and 82%, respectively.

CONCLUSIONS

A novel point-of-care device has excellent diagnostic accuracy for detecting electrophysiological abnormality in the sural nerve of patients who have diabetes. This automated device represents an alternative to conventional nerve conduction studies for the diagnosis of diabetic sensorimotor polyneuropathy.

Authors+Show Affiliations

Toronto General Hospital, 200 Elizabeth St., Room EN-12-217, Toronto, Ontario, Canada M5G 2C4. bruce.perkins@uhn.on.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

16936147

Citation

Perkins, Bruce A., et al. "Validation of a Novel Point-of-care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy." Diabetes Care, vol. 29, no. 9, 2006, pp. 2023-7.
Perkins BA, Grewal J, Ng E, et al. Validation of a novel point-of-care nerve conduction device for the detection of diabetic sensorimotor polyneuropathy. Diabetes Care. 2006;29(9):2023-7.
Perkins, B. A., Grewal, J., Ng, E., Ngo, M., & Bril, V. (2006). Validation of a novel point-of-care nerve conduction device for the detection of diabetic sensorimotor polyneuropathy. Diabetes Care, 29(9), 2023-7.
Perkins BA, et al. Validation of a Novel Point-of-care Nerve Conduction Device for the Detection of Diabetic Sensorimotor Polyneuropathy. Diabetes Care. 2006;29(9):2023-7. PubMed PMID: 16936147.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Validation of a novel point-of-care nerve conduction device for the detection of diabetic sensorimotor polyneuropathy. AU - Perkins,Bruce A, AU - Grewal,Jaspreet, AU - Ng,Eduardo, AU - Ngo,Mylan, AU - Bril,Vera, PY - 2006/8/29/pubmed PY - 2007/1/9/medline PY - 2006/8/29/entrez SP - 2023 EP - 7 JF - Diabetes care JO - Diabetes Care VL - 29 IS - 9 N2 - OBJECTIVE: The diagnosis of diabetic sensorimotor polyneuropathy using objective electrophysiological tests is hindered by limited access to the specialized laboratories and technicians that perform and interpret them. We evaluated the performance characteristics of a novel portable and automated point-of-care nerve conduction study device, which can be operated by nontechnical personnel, and compared it with conventional nerve conduction studies performed in a specialist setting. RESEARCH DESIGN AND METHODS: Seventy-two consecutive patients with diabetes (8 type 1, 64 type 2) from a diabetes and a neuropathy outpatient clinic were evaluated concurrently with conventional nerve conduction studies (the reference standard) and the point-of-care device for sural nerve function (sural nerve amplitude potentials in microvolts [microV]). RESULTS: Sural nerve amplitude potentials measured by the point-of-care device shared very strong correlation with the reference standard (Spearman's correlation coefficient 0.95, P < 0.001). The Bland and Altman method yielded agreement despite a small systematic underestimation by the point-of-care device of 1.2 +/- 3.4 microV. Despite this small systematic bias, the sensitivity and specificity of normal and abnormal sural nerve amplitude potentials measured by the point-of-care device for the detection of diabetic sensorimotor polyneuropathy defined by standard clinical and electrophysiological criteria were 92 and 82%, respectively. CONCLUSIONS: A novel point-of-care device has excellent diagnostic accuracy for detecting electrophysiological abnormality in the sural nerve of patients who have diabetes. This automated device represents an alternative to conventional nerve conduction studies for the diagnosis of diabetic sensorimotor polyneuropathy. SN - 0149-5992 UR - https://www.unboundmedicine.com/medline/citation/16936147/Validation_of_a_novel_point_of_care_nerve_conduction_device_for_the_detection_of_diabetic_sensorimotor_polyneuropathy_ L2 - http://care.diabetesjournals.org/cgi/pmidlookup?view=long&amp;pmid=16936147 DB - PRIME DP - Unbound Medicine ER -